64 assets in Lung Adenocarcinoma

Therapeutic assets addressing Lung Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
nxp900 Lung Adenocarcinoma	Nuvectis Pharma, Inc.	P1	CC (43)
Avelumab Lung Adenocarcinoma	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	P1	CC (42)
Amt-151 Lung Adenocarcinoma	Multitude Therapeutics Inc.	P1	CC (41)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Lung Adenocarcinoma	Anusha Kalbasi	P1	CC (41)
Cromoglicic Acid Lung Adenocarcinoma	Carcinex Inc	P1	CC (41)
Fludeoxyglucose Lung Adenocarcinoma	Anusha Kalbasi	P1	CC (41)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Lung Adenocarcinoma	Anusha Kalbasi	P1	CC (41)
Autologous, Engineered T Cells Targeting Tp53 R248Q Lung Adenocarcinoma	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Early P1	C (38)
Binimetinib Lung Adenocarcinoma	Roswell Park Cancer Institute	Early P1	C (38)
Palbociclib Lung Adenocarcinoma	Roswell Park Cancer Institute	Early P1	C (38)
Diclofenac Lung Adenocarcinoma	Hacettepe University	N/A	D (30)
Marcaine Lung Adenocarcinoma	Hacettepe University	N/A	D (30)
Nepenthe Lung Adenocarcinoma	Hacettepe University	N/A	D (30)
Lifei Xiaoji Wan Lung Adenocarcinoma	Henan University of Traditional Chinese Medicine	N/A	NR ()

Showing 51 to 64 of 64 assets

PreviousPage 2 of 2Next